General MedicationsORALGeneric
DAKLINZA
DACLATASVIR DIHYDROCHLORIDE
Standard Dose
EQ 30MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview DAKLINZA is listed in Drugs@FDA under application 206843 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient DACLATASVIR DIHYDROCHLORIDE Form and strength TABLET;ORAL - EQ 30MG BASE Sponsor BRISTOL-MYERS SQUIBB Submission history Latest submission status date: 2019-10-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview DAKLINZA is listed in Drugs@FDA under application 206843 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DACLATASVIR DIHYDROCHLORIDE Form and strength TABLET;ORAL - EQ 30MG BASE Sponsor BRISTOL-MYERS SQUIBB Submission history Latest submission status date: 2019-10-16 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.